Bicara Leads Trio of US Biotech IPOs Raising $703 Million
This article is for subscribers only.
A trio of biotech companies sold shares in their initial public offerings on Thursday, an encouraging sign for a sector whose new entrants have lately struggled.
Bicara Therapeutics Inc. expanded its IPO to sell 17.5 million shares at $18 each, at the top of the price range, to raise $315 million, according to a statement. The company had boosted the number of shares on Wednesday, a regulatory filing showed.